The NMDA receptor NR2B subtype selective antagonist Ro 25-6981 aggravates paroxysmal dyskinesia in the dt sz mutant

By Richter A.  

European Journal of Pharmacology, Vol. 458, Iss. 1, 2003-01 ,pp. : 107-110

Elsevier

Access to resources Recommend Favorite

Pharmacological and genetic evidence indicates that combined inhibition of NR2A and NR2B subunit containing NMDA receptors is required to disrupt prepulse inhibition

By Spooren Will   Mombereau Cedric   Maco Martine   Gill Rammy   Kemp John   Ozmen Laurence   Nakanishi Shigetada   Higgins Guy  

Psychopharmacology, Vol. 175, Iss. 1, 2004-08 ,pp. : 99-105

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacological heterogeneity of NMDA receptors: characterization of NR1a/NR2D heteromers expressed in Xenopus oocytes

By Buller A.L.   Monaghan D.T.  

European Journal of Pharmacology, Vol. 320, Iss. 1, 1997-02 ,pp. : 87-94

Elsevier

Access to resources Recommend Favorite

The effect of (+/-)-CP-101,606, an NMDA receptor NR2B subunit selective antagonist, in the Morris watermaze

By Guscott M.R.   Clarke H.F.   Murray F.   Grimwood S.   Bristow L.J.   Hutson P.H.  

European Journal of Pharmacology, Vol. 476, Iss. 3, 2003-08 ,pp. : 193-199

Elsevier

Access to resources Recommend Favorite

The NMDA Receptor NR2B Subunit: A Valid Therapeutic Target for Multiple CNS Pathologies

By  

Current Medicinal Chemistry, Vol. 11, Iss. 3, 2004-02 ,pp. : 389-396

Bentham Science Publishers

Access to resources Recommend Favorite